Immunic, Inc. – NASDAQ:IMUX

Add to watchlist

$0.944

-0.08

-8.4%

Market closed

Open in about 11 hours

-25.36%

month

-25.36%

quarter

-35.63%

year

Market Cap	94.13M
Enterprise value	N/A

P/E	-0.42
EV/Sales	N/A
EV/EBITDA	0.49
Price/Sales	N/A
Price/Book	0.40
PEG ratio	-0.11
EPS	-1.83

Revenue	N/A
EBITDA	-95.74M
Income	-97.92M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Immunic, Inc. (NASDAQ:IMUX): Profit margin
Jun 2023	0	-23.99M
Sep 2023	0	-22.76M
Dec 2023	0	-21.57M
Mar 2024	0	-29.58M

Immunic Financials Estimate

Q Y

Immunic, Inc. (NASDAQ:IMUX): Analyst Estimates
Mar 2024	0	-29.58M
Sep 2025	0	-12.94M
Oct 2025	0	-19.45M
Dec 2025	0	-20.43M

Analysts Price target
Financials & Ratios estimates

Immunic, Inc. (NASDAQ:IMUX): Debt to assets
Jun 2023	88739000	19.45M	21.92%
Sep 2023	66977000	18.57M	27.73%
Dec 2023	54299000	25.36M	46.72%
Mar 2024	104155000	20.57M	19.76%

Immunic, Inc. (NASDAQ:IMUX): Cash Flow
Jun 2023	-19.97M	4.33M	96
Sep 2023	-17.31M	-44K	282
Dec 2023	-14.02M	-165K	604
Mar 2024	-23.96M	-31K	74.46M

Immunic alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Immunic, Inc. (NASDAQ:IMUX): Employee count
Aug 2023	73
Sep 2023	75
Oct 2023	75
Nov 2023	75
Dec 2023	80
Jan 2024	80
Feb 2024	80
Mar 2024	77
Apr 2024	77
May 2024	77
Jun 2024	80
Jul 2024	80

Immunic
Hedge Funds Holdings Q1 2023

32.04% -49.45%

of IMUX is owned by hedge funds

33 -29

hedge funds hold IMUX stock

10.19M -14.71M

shares is hold by hedge funds

IMUX hedge funds holdings changes

Immunic, Inc. (NASDAQ:IMUX): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	14000	0
Nov 2024	87300	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	12 Nov 2024	RUDICK RICHARD ALAN director director	Common Stock	87,300	$1.15	$100,395
Purchase	26 Feb 2024	VITT DANIEL director, officer..	Common Stock	14,000	$1.31	$18,340
Purchase	15 May 2023	WHALEY GLENN officer: Chief Fi..	Common Stock	5,000	$1.75	$8,750
Purchase	14 Dec 2022	NEERMANN JOERG director director	Common Stock	47,000	$1.26	$59,032
Purchase	13 Dec 2022	NEERMANN JOERG director director	Common Stock	35,000	$1.25	$43,610
Purchase	23 Nov 2022	NEERMANN JOERG director director	Common Stock	18,000	$1.39	$25,020
Purchase	22 Nov 2022	VITT DANIEL director, officer..	Common Stock	8,000	$1.35	$10,800
Purchase	7 Nov 2022	WHALEY GLENN officer: Chief Fi..	Common Stock	5,000	$1.5	$7,475
Purchase	3 Jun 2022	WHALEY GLENN officer: Chief Fi..	Common Stock	3,500	$3.05	$10,658
Purchase	3 Jun 2022	VITT DANIEL director, officer..	Common Stock	5,000	$3.1	$15,500

Immunic
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 22 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 6 Aug 2023	Q2 2023 Earnings Call Transcript

IMUX earnings call transcripts

Immunic
Executives

Insider	Age	Compensation
Dr. Daniel Vitt (1968) Chief Executive Officer, Pres & Director	57	$609,450
Dr. Andreas Muehler Ph.D., M.D. (1964) Chief Medical Officer	61	$545,020
Mr. Glenn Whaley (1968) Vice President of Fin. and Principal Financial & Accounting Officer	57	$488,180
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A (1971) Executive Chairman	54	$362,640

Immunic
Latest News

Tuesday, 26 November 2024
06:30	Immunic, Inc. to Participate in Investor Conference in December	prnewswire.com
Saturday, 16 November 2024
12:59	Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI	proactiveinvestors.com
Wednesday, 13 November 2024
09:39	Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet	proactiveinvestors.com
06:30	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology	prnewswire.com
Saturday, 9 November 2024
08:37	Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 7 November 2024
08:58	Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones	proactiveinvestors.com
06:30	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update	prnewswire.com
Thursday, 31 October 2024
06:30	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update	prnewswire.com
Tuesday, 29 October 2024
06:30	Immunic to Participate in Industry, Scientific and Investor Conferences in November	prnewswire.com
Tuesday, 22 October 2024
09:16	Immunic Phase 3 MS study advances following positive recommendation from independent committee	proactiveinvestors.com
06:30	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis	prnewswire.com
Wednesday, 18 September 2024
08:43	Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS Congress	proactiveinvestors.com
06:30	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis	prnewswire.com
Saturday, 7 September 2024
08:30	Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI	proactiveinvestors.com
Wednesday, 4 September 2024
08:44	Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial	proactiveinvestors.com
06:30	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome	prnewswire.com
Wednesday, 28 August 2024
09:41	Immunic to highlight lead asset's promise at upcoming Multiple Sclerosis R&D Day	proactiveinvestors.com
06:30	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September	prnewswire.com
Friday, 9 August 2024
18:55	Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
09:10	Immunic strengthens leadership team as MS trials advance toward key milestones	proactiveinvestors.com
06:30	Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update	prnewswire.com
Thursday, 1 August 2024
06:30	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update	prnewswire.com
Saturday, 27 July 2024
11:17	Immunic chief scientific officer shares insights on innovative MS therapy - ICYMI	proactiveinvestors.com
Wednesday, 24 July 2024
09:20	Immunic appoints Simona Skerjanec to board of directors	proactiveinvestors.com
Tuesday, 9 July 2024
08:33	Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch	proactiveinvestors.com
06:30	Immunic Appoints Jason Tardio as Chief Operating Officer and President	prnewswire.com
Tuesday, 28 May 2024
06:30	Immunic to Participate in Industry and Scientific Conferences in June	prnewswire.com
Thursday, 23 May 2024
06:00	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying	investorplace.com
Monday, 20 May 2024
06:00	Immunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseases	https://www.proactiveinvestors.com
Wednesday, 8 May 2024
14:20	Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript	seekingalpha.com

Ideas & Opinions

Seeking Alpha 9 Jun 2025

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
Seeking Alpha 28 Apr 2025

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
Seeking Alpha 19 Oct 2023

Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis
Seeking Alpha 25 May 2023

Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender
Seeking Alpha 15 May 2023

Immunic: Proof Of Concept With IMU-856 Provides Additional Shot On Goal
Seeking Alpha 7 Feb 2023

Immunic: Multiple Sclerosis Data In H2 2023 Could Provide Major Shift
Seeking Alpha 12 Oct 2022

Immunic: New MS Drugs Need Extreme Product Differentiation

Frequently Asked Questions (FAQ)

What's the price of Immunic stock today?

One share of Immunic stock can currently be purchased for approximately $0.94.
When is Immunic's next earnings date?

Unfortunately, Immunic's (IMUX) next earnings date is currently unknown.
Does Immunic pay dividends?

No, Immunic does not pay dividends.
How much money does Immunic make?

Immunic has a market capitalization of 94.13M.
What is Immunic's stock symbol?

Immunic, Inc. is traded on the NASDAQ under the ticker symbol "IMUX".
What is Immunic's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Immunic?

Shares of Immunic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Immunic's key executives?
Immunic's management team includes the following people:
- Dr. Daniel Vitt Chief Executive Officer, Pres & Director(age: 57, pay: $609,450)
- Dr. Andreas Muehler Ph.D., M.D. Chief Medical Officer(age: 61, pay: $545,020)
- Mr. Glenn Whaley Vice President of Fin. and Principal Financial & Accounting Officer(age: 57, pay: $488,180)
- Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A Executive Chairman(age: 54, pay: $362,640)
How many employees does Immunic have?

As Jul 2024, Immunic employs 80 workers, which is 4% more then previous quarter.
When Immunic went public?

Immunic, Inc. is publicly traded company for more then 11 years since IPO on 17 Apr 2014.
What is Immunic's official website?

The official website for Immunic is immunic-therapeutics.com.
Where are Immunic's headquarters?

Immunic is headquartered at 1200 Avenue of the Americas, New York, NY.
How can i contact Immunic?

Immunic's mailing address is 1200 Avenue of the Americas, New York, NY and company can be reached via phone at +33 22559818.

Immunic, Inc.

immunic-therapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

+33 22559818

1200 Avenue of the Americas
New York, NY 10036

CIK: 0001280776
ISIN: US4525EP1011
CUSIP: 4525EP101